CMS Just Made Big Pharma's Worst Nightmare Harder to Wake Up From
CMS proposed locking in Medicare-negotiated drug prices with limited renegotiation options, turning what pharma hoped was a flexible pricing regime into something much closer to a permanent step-down. For companies sitting on aging blockbusters, the math just changed dramatically.
Imagine you negotiate your rent with your landlord. You agree on a number, sign the lease, and move in. Now imagine your landlord passes a new rule: that rent you agreed to? It's basically permanent, adjusted only for inflation, and there are almost no circumstances under which you can renegotiate. Welcome to the pharma industry's Friday.
CMS just published a proposed rule that would make Medicare's negotiated drug prices under the Inflation Reduction Act (IRA) far more durable and far less revisable than many drugmakers had been counting on. The proposal doesn't change which drugs get negotiated. It changes what happens after the handshake. And for companies sitting on aging blockbusters, that distinction is worth billions.
The Price You Set Is the Price You Keep
Under the IRA, CMS negotiates a Maximum Fair Price (MFP) for selected high-cost drugs. Once that price kicks in, it already doesn't get renegotiated every year. Instead, it ticks up by an annual inflation adjustment, and that's it.
But there was always some ambiguity about when and how manufacturers could trigger a do-over. Maybe a drug picked up a big new indication. Maybe clinical data shifted. The statute left room for renegotiation under certain conditions, and pharma companies modeled their forecasts accordingly.
The June 2026 proposed rule narrows those conditions significantly. It codifies a structured renegotiation framework starting with the 2029 pricing cycle, and it raises the bar for reopening any deal. A drug's MFP can only be revisited if one of three things happens: the drug crosses a new monopoly-age threshold, it gains a major new FDA-approved indication, or there's a material change in key pricing factors that CMS determines would shift the MFP by at least 15%.
If none of those triggers fire? The price stays locked, adjusted only for inflation. No new evidence, no updated cost data, no fresh utilization numbers will automatically reopen the deal.
Why Pharma Was Counting on Flexibility
To understand why this matters, you need to think about how pharma companies value their own products.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
A drug like Eliquis (a blood thinner) or Stelara (used for psoriasis and Crohn's disease) doesn't just generate revenue today. Its value to the company is the sum of all future cash flows, discounted back to the present. When analysts build financial models for these drugs, they project revenue curves years into the future, and the shape of those curves depends heavily on pricing assumptions.
Before this rule, many companies were modeling a scenario where they could, at some point, make a case to CMS for a higher or at least renegotiated MFP. Maybe a new study would show expanded benefits. Maybe manufacturing costs would rise enough to justify a conversation. That optionality had real value baked into their projections.
CMS just took most of that optionality off the table. The 15% materiality threshold alone is a high bar; it means minor shifts in clinical evidence or market dynamics won't even get you to the negotiating table. And tying renegotiation to specific cycle timelines (rather than allowing it whenever circumstances change) means prices stay locked between those decision points, sometimes for years.
The Pricing Cliff Just Got Steeper
Analysts already talk about an "IRA pricing cliff" for drugs that get selected for negotiation. It works like this: a small-molecule drug hits seven years on the market (11 for biologics), becomes eligible for selection for negotiation, and then faces a steep, one-time price cut on its Medicare revenue once the negotiated price takes effect two years later. For the first 10 negotiated drugs, those cuts landed in the range of 38% to 79% off 2023 list prices.
That cliff was already painful. But companies could at least tell investors, "Look, the price drops, but there's a path to renegotiate as things evolve." This proposed rule makes that cliff look more like a permanent step-down. Once you fall, you don't climb back.
The drugs most exposed share four traits: heavy Medicare patient populations, years of monopoly remaining before generics arrive, concentration in Part D (oral and self-administered drugs), and limited ability to offset Medicare cuts with higher commercial prices. Think cardiovascular meds, diabetes treatments, and certain oncology drugs prescribed to patients 65 and older.
Who Feels the Pain?
The first 10 negotiated drugs (prices effective January 2026) include household names: Eliquis, Xarelto, Jardiance, Januvia, Entresto, Enbrel, Imbruvica, Stelara, Farxiga, and Novo Nordisk's insulin aspart family (Fiasp/NovoLog). Fifteen more drugs joined the program for 2027, including Ozempic and Wegovy. By 2029, CMS will be negotiating prices for 20 drugs per year.
For companies like Bristol-Myers Squibb, AbbVie, and Johnson & Johnson, the immediate financial hit has been described by analysts as "manageable." UBS and J.P. Morgan characterized the first-round discounts as roughly in line with expectations, not an existential event. These companies have publicly stated they can still meet long-term financial targets.
But "manageable" doesn't mean painless. Analyst models are already being rewritten. The adjustments are subtle but significant: shorter cash-flow tails for Medicare-heavy small molecules, earlier plateau assumptions for U.S. revenue, and explicit "IRA haircuts" of 50-60% on the Medicare book when a drug is expected to be selected. Terminal growth rates and terminal margins are being marked down for affected brands.
PhRMA Is Not Happy (Surprise)
PhRMA, the pharmaceutical industry's main trade group, has pushed back hard. Its position: this isn't really "negotiation" at all. It's government price-setting dressed up with a friendlier name. PhRMA has argued that CMS went beyond what Congress authorized, that the process gives manufacturers too little input, and that locking in prices with limited renegotiation could discourage investment in drugs for chronic conditions that primarily affect Medicare patients.
The legal fight continues. Since 2023, more than 10 lawsuits have challenged the IRA's negotiation program on constitutional grounds, including claims under the First, Fifth, and Eighth Amendments. So far, no court has blocked the program. The first negotiated prices took effect on January 1, 2026, right on schedule. But the shift to formal rulemaking (this proposed rule is the beginning of that process) could open new legal angles, particularly around whether CMS's specific threshold choices and renegotiation restrictions survive administrative-law scrutiny.
The Bigger Picture: What Gets Built Next
Credit analysts at Moody's see the IRA as a structural headwind for the industry's margins over the next decade. But the more interesting effect might be on what pharma decides to build. The seven-year selection timeline for small molecules (versus 11 years for biologics) is already pushing companies to tilt R&D toward biologics and rare diseases, where IRA exposure is either delayed or where patient volumes are smaller.
The CBO has estimated these pricing provisions could reduce the number of new drugs by about 1% over 30 years. Whether that's a reasonable trade-off for lower drug costs is, of course, the trillion-dollar policy question.
What's not debatable: CMS just made the rules of the game clearer, and tougher. For late-lifecycle blockbusters with heavy Medicare exposure, the path forward just got a lot more predictable, and a lot less profitable.
Clinical & Regulatory
4 min read
Roche Just Crashed the Obesity Party With a Number Nobody Expected
Roche's obesity drug enicepatide posted 22.5% weight loss in 48 weeks, landing squarely in Zepbound territory and turning Roche from a latecomer into a legitimate contender. The real question: can it compete with what Lilly and Novo are cooking up next?
